Hostname: page-component-586b7cd67f-r5fsc Total loading time: 0 Render date: 2024-11-28T22:48:03.703Z Has data issue: false hasContentIssue false

Looking though the Past, Present and Future of TMS-EEG

Published online by Cambridge University Press:  19 July 2023

S. N. Martins*
Affiliation:
Centro Hospitalar Tâmega e Sousa, Penafiel
C. Romano
Affiliation:
Centro Hospitalar Tâmega e Sousa, Penafiel
B. Ribeiro
Affiliation:
Centro Hospitalar Tâmega e Sousa, Penafiel
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Psychiatry has been diagnosing its pathologies through the evaluation of the symptoms reported by patients, relying on a few complementary exams to exclude organic causes. Studies about transcranial magnetic stimulation and electroencephalography (TMS-EEG) are bringing, from a clinical point of view, crucial information to characterize the different pathophysiological biomarkers of the psychiatric diseases, leading not only to the evolution of diagnosis, but also to an improved, more individualized treatment.

Objectives

Characterizing the state of the art of TMS-EEG and its use in psychiatric diagnosis and treatments of different diseases.

Methods

We undertook a narrative literature review by performing a search on PubMed for English-written articles from the last 10 years. The query used was “TMS-EEG”; “TMS-EEG” AND “Schizophrenia” OR “Major Depressive Disorder” OR “Bipolar Disorder”.

Results

Transcranial magnetic stimulation (TMS) is a safe and reliable method of non-invasive brain stimulation that allows for the local activation of cortical areas through electromagnetic induction. When combining this method with electroencephalography (EEG), it enables the underlying mechanisms of brain diseases.

TMS is a powerful therapeutic technic in Major Depressive Disorder (MDD). The literature refers to an enhanced N45 and N100 amplitude, which indicates a baseline cortical inhibition that can indicate a depressed state, which can be used as a clinical biomarker to evaluate TMS treatments.

In Schizophrenia (SCZ), TMS-EEG reveals a decreased cortical inhibition and excitation. Indices of inhibition and excitation reductions were also related to cognitive deficits.

The current studies regarding Bipolar Disorder (BD) are not so consistent, revealing that there are shared neural pathways with MDD and SCZ. This is a pathology often misdiagnosed with MDD, so biomarkers would help to diagnose BD earlier and improve its prognostic.

Conclusions

TMS-EEG can be used to provide more accurate neural targets, leading to more powerful and personalized interventions in psychiatric disorders, as well as more accurate diagnoses.

As for future studies, it would be relevant to assess not only TMS treatment effects, but also pharmacological results in these different pathologies.

Disclosure of Interest

None Declared

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of the European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.